JP2014524480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524480A5 JP2014524480A5 JP2014527329A JP2014527329A JP2014524480A5 JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5 JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- active agent
- formulation
- pharmaceutical
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526940P | 2011-08-24 | 2011-08-24 | |
| US61/526,940 | 2011-08-24 | ||
| US201161551506P | 2011-10-26 | 2011-10-26 | |
| US61/551,506 | 2011-10-26 | ||
| PCT/US2012/052304 WO2013028989A1 (en) | 2011-08-24 | 2012-08-24 | Formulations of active agents for sustained release |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524480A JP2014524480A (ja) | 2014-09-22 |
| JP2014524480A5 true JP2014524480A5 (enExample) | 2015-10-15 |
| JP6169079B2 JP6169079B2 (ja) | 2017-07-26 |
Family
ID=47746903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527329A Active JP6169079B2 (ja) | 2011-08-24 | 2012-08-24 | 徐放のための活性剤の製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130084277A1 (enExample) |
| EP (2) | EP2747832A4 (enExample) |
| JP (1) | JP6169079B2 (enExample) |
| CN (1) | CN104023784B (enExample) |
| CA (1) | CA2846209C (enExample) |
| HK (1) | HK1199418A1 (enExample) |
| WO (1) | WO2013028989A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| CN102131516B (zh) | 2008-06-27 | 2016-03-16 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US11052132B2 (en) | 2014-05-08 | 2021-07-06 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3220936A4 (en) * | 2014-11-21 | 2018-08-22 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
| CN114652817B (zh) | 2015-02-09 | 2026-04-17 | 费斯生物制药公司 | 用于治疗肌肉疾病和病症的方法和组合物 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| MX2018013546A (es) | 2016-05-06 | 2019-04-22 | Phasebio Pharmaceuticals Inc | Proteinas de fusion de elp para liberacion controlada y sostenida. |
| CN119390817A (zh) * | 2024-10-14 | 2025-02-07 | 华南理工大学 | 一种可编程的多重修饰长效缓释类弹性蛋白elp载体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
| EP2664340B1 (en) * | 2005-06-24 | 2020-02-12 | Duke University | A direct drug delivery system based on thermally responsive biopolymers |
| US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| WO2007073486A2 (en) * | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US7709227B2 (en) * | 2006-01-04 | 2010-05-04 | Phasebio Pharmaceuticals, Inc. | Multimeric ELP fusion constructs |
| CA2663047A1 (en) * | 2006-09-06 | 2008-03-13 | Phase Bioscience, Inc. | Therapeutic elastin-like polypeptide (elp) fusion proteins |
| PL2155169T3 (pl) * | 2007-06-08 | 2016-09-30 | Formulacja newirapiny o przedłużonym uwalnianiu | |
| EP2190872B1 (en) * | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| CN102131516B (zh) * | 2008-06-27 | 2016-03-16 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| US20110288001A1 (en) * | 2008-12-18 | 2011-11-24 | Homayoun Sadeghi | Biologically active proteins activatable by peptidase |
| US9029505B2 (en) * | 2009-08-14 | 2015-05-12 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
| CA2873553C (en) * | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
-
2012
- 2012-08-24 CN CN201280052426.0A patent/CN104023784B/zh active Active
- 2012-08-24 US US13/594,383 patent/US20130084277A1/en not_active Abandoned
- 2012-08-24 EP EP12826427.2A patent/EP2747832A4/en not_active Withdrawn
- 2012-08-24 JP JP2014527329A patent/JP6169079B2/ja active Active
- 2012-08-24 EP EP22213287.0A patent/EP4295858A1/en active Pending
- 2012-08-24 CA CA2846209A patent/CA2846209C/en active Active
- 2012-08-24 HK HK14113095.1A patent/HK1199418A1/xx unknown
- 2012-08-24 WO PCT/US2012/052304 patent/WO2013028989A1/en not_active Ceased
-
2013
- 2013-12-06 US US14/099,590 patent/US20140171370A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524480A5 (enExample) | ||
| AU2023237119B2 (en) | Buffered formulations of exendin (9-39) | |
| ES2992698T3 (en) | Combination of an insulin and a glp-1 agonist | |
| US20250000933A1 (en) | Terlipressin compositions and their methods of use | |
| CA2814057C (en) | Intravenous composition comprising paracetamol and ibuprofen | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2018528242A (ja) | 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 | |
| JP2020500864A5 (enExample) | ||
| CN110678194A (zh) | 奥曲肽注射液 | |
| ES3062720T3 (en) | Sublingual epinephrine tablets | |
| JP2020510043A5 (enExample) | ||
| JP2009506978A5 (enExample) | ||
| JP2020510028A5 (enExample) | ||
| JP2019507174A5 (enExample) | ||
| JP2014502608A5 (enExample) | ||
| JP2008505087A5 (enExample) | ||
| JP2009514869A (ja) | ヒト成長ホルモンパッチ製剤 | |
| JP2016503406A5 (enExample) | ||
| CN114096269A (zh) | 高浓度胰岛素制剂 | |
| Kesavadev et al. | Newer insulins on the horizon | |
| HK40120596A (en) | Terlipressin compositions and their methods of use | |
| HK40014065B (en) | Terlipressin composition for use in treating ascites | |
| HK40014065A (en) | Terlipressin composition for use in treating ascites | |
| Rubinstein | Safety Of Nanomicellar Vasoactive Intestinal Peptide In Mice-Implications For Pulmonary Arterial Hypertension |